In vitro inhibition of CYP2D6 activity by fenfluramine.

被引：0
|
作者：
Marcucci, K
Gotschall, R
Kearns, GL
Leeder, JS
机构：
[1] Childrens Mercy Hosp, Sect Clin Pharmacol & Exp Ther, Kansas City, MO 64108 USA
[2] Childrens Mercy Hosp, NICHD, PPRU, Kansas City, MO 64108 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1999年 / 65卷 / 02期
关键词：
D O I：
10.1016/S0009-9236(99)80099-X
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI99
引用
收藏
页码：142 / 142
页数：1
相关论文
共 50 条
  • [1] Time dependent inhibition of CYP2D6 by fenfluramine and norfenfluramine
    Chen, Weichao G.
    Ortiz, Alvaro
    Usmani, Khawja A.
    Palamar, Safet
    Cerny, Matthew
    Smith, Brian
    Sadeque, Abu
    DRUG METABOLISM REVIEWS, 2006, 38 : 126 - 126
  • [2] Inhibition of CYP2D6 activity by bupropion
    Kotlyar, M
    Brauer, LH
    Tracy, TS
    Hatsukami, DK
    Harris, J
    Bronars, CA
    Adson, DE
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (03) : 226 - 229
  • [3] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [4] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [5] The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity
    Dinh, Jean C.
    Boone, Erin C.
    Staggs, Vincent S.
    Pearce, Robin E.
    Wang, Wendy Y.
    Gaedigk, Roger
    Leeder, James Steven
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (03) : 646 - 654
  • [6] STEREOSELECTIVE INHIBITION OF CYP2D6 BY CHLORPHENIRAMINE
    SALCEDO, JA
    YASUDA, SU
    MURPHY, MP
    WOOSLEY, RL
    FLOCKHART, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (02) : 149 - 149
  • [7] The influence of clomipramine on CYP2D6 activity
    Szewczuk-Boguslawska, Monika
    Kiejna, Andrzej
    Grzesiak, Magdalena
    Beszlej, Jan Aleksander
    Chlebowska, Iwona
    Orzechowska-Juzwenko, Krystyna
    Milejski, Piotr
    PSYCHIATRIA POLSKA, 2007, 41 (02) : 243 - 249
  • [8] QSAR studies of quinidine inhibition of CYP2D6
    Hutzler, JM
    Wienkers, LC
    DRUG METABOLISM REVIEWS, 2002, 34 : 172 - 172
  • [9] Importance of CYP2D6 metabolism in the in vitro antiestrogenic activity of toremifene and tamoxifen
    Coss, C.
    Barrett, C.
    Kim, J.
    Li, C.
    Dalton, J. T.
    Veverka, K. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Inhibition of CYP2D6 by antipsychotic drugs.
    Shin, JG
    Soukhova, N
    Desta, Z
    Flockhart, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 188 - 188
12345